Lipid Nanoparticle (LNP) News Brief: March 17-24, 2025
Frontiers in Nanotechnology: Published research article on RNA-lipid nanoparticle therapeutics for women's health, focusing on gynecological and obstetric conditions.
Serina Therapeutics: Presented data on non-immunogenic POZ-lipid technology for LNPs at the ACS Spring Meeting.
Croda/Avanti Research: Announced strategic collaboration with Certest to expand ionizable lipid offerings for LNP drug development.
Prime Medicine: Unveiled AATD gene correction program using their proprietary liver-targeted LNP technology.
4th LNP Formulation & Process Development Summit: Major conference bringing together over 230 LNP experts to address challenges in LNP design, delivery, and manufacturing.
Detailed News Summaries
Frontiers in Nanotechnology: RNA-LNP Therapeutics for Women's Health
This research article evaluates the potential of RNA-lipid nanoparticle therapeutics for addressing women’s health challenges, including gynecological cancers, endometriosis, and viral infections. The study highlights how LNPs can enhance RNA delivery efficiency through targeted ligand conjugation, improving stability and biodistribution compared to traditional methods.
While mRNA-LNP vaccines for COVID-19 and RSV are cited as successful precedents, the authors emphasize unresolved challenges such as off-target effects, immune activation risks, and potential impacts on reproductive systems during pregnancy. The review identifies ongoing clinical trials exploring LNPs for HPV-related cancers and endometriosis therapies, underscoring the need for further safety evaluations in female-specific biological contexts.
Release Date: March 19, 2025
Website Link: https://www.frontiersin.org/journals/nanotechnology/articles/10.3389/fnano.2025.1475969/full
Related Institute: Frontiers in Nanotechnology (Lausanne, Switzerland)
Serina Therapeutics: Non-Immunogenic POZ-Lipid Technology
Serina Therapeutics presented preclinical data at the ACS Spring 2025 Meeting demonstrating that its POZ-lipid technology avoids immune responses in rats, unlike traditional PEGylated lipids. Dr. Randall Moreadith, Chief Development Officer, revealed that repeated dosing of POZ-lipid LNPs did not trigger IgM or IgG antibodies, whereas PEG-lipids caused strong antibody reactions.
This innovation addresses safety concerns linked to PEGylated mRNA vaccines, such as anaphylaxis risks, and positions POZ-lipids as a safer alternative for gene therapies targeting neurological diseases. The findings could accelerate the development of next-generation LNPs with reduced immunogenicity.
Release Date: March 24, 2025
Location: Huntsville, Alabama, USA
Croda/Avanti Research and Certest Collaboration
Croda’s Avanti Research announced a partnership with Certest Biotec to expand access to novel ionizable lipids for LNP development. The collaboration integrates Certest’s lipid library with Croda’s manufacturing infrastructure to support drug delivery from preclinical stages to commercialization.
Amy Pasley, Global Business Director at Croda, emphasized the partnership’s role in overcoming LNP formulation challenges, particularly in nucleic acid delivery. Certest’s Nelson Fernandes highlighted the joint commitment to producing GMP-grade lipids, aiming to accelerate therapies for diseases requiring targeted RNA delivery.
Release Date: March 17, 2025
Locations:
Croda/Avanti Research: Alabaster, Alabama, USA
Certest Biotec: Zaragoza, Spain
Prime Medicine: AATD Gene Correction Program
Prime Medicine unveiled a preclinical program using prime editing technology delivered via liver-targeted LNPs to correct the E342K mutation in alpha-1 antitrypsin deficiency (AATD). The therapy achieved 72% gene correction in humanized mice, restoring wild-type AAT protein to normal levels.
The company plans to file an IND/CTA by mid-2026, positioning this as a potential one-time curative treatment for AATD’s liver and lung manifestations. Preclinical data also demonstrated >50% editing efficiency in non-human primates with no detected off-target effects, leveraging GalNAc-LNP biodistribution advantages.
Release Date: March 19, 2025
Website Link: https://www.clinicaltrialvanguard.com/news/prime-medicine-unveils-aatd-gene-correction-treatment-program/
Location: Cambridge, Massachusetts, USA
4th LNP Formulation & Process Development Summit
This industry summit convened 230+ experts to address LNP development bottlenecks, featuring three specialized tracks:
Analytical Development & Characterization: Strategies for improving LNP stability and reproducibility.
Formulation & Delivery: Advances in extrahepatic targeting and ionizable lipid design.
Process Development & Manufacturing: Scaling production for clinical and commercial use.
Key participants included Arbor Biotechnologies, Pfizer, and Takeda, with workshops on lipid library optimization and CMC challenges. The event highlighted regulatory progress, including Arbor’s IND approval for an LNP-mediated hyperoxaluria therapy, and featured networking sessions to foster collaborations.
Release Date: March 18, 2025
Website Link: https://lnp-formulation-process-development-pharma.com/
Location: The Westin Copley Place, Boston, Massachusetts, USA
Conclusion
The March 17–24, 2025 period marked significant advancements in LNP technology, spanning women’s health applications, novel lipid chemistries, strategic partnerships, and large-scale industry collaboration. Serina’s non-immunogenic POZ-lipids and Prime Medicine’s gene-editing LNPs exemplify progress in therapeutic safety and precision, while the Croda-Certest partnership underscores growing demand for diversified lipid libraries. The 4th LNP Summit reinforced the field’s focus on scalable manufacturing and targeted delivery, setting the stage for accelerated clinical translation of LNP-based therapies.
Comments